171 related articles for article (PubMed ID: 28529646)
1. Peptide vaccination in the presence of adjuvants in patients after hematopoietic stem cell transplantation with CD4+ T cell reconstitution elicits consistent CD8+ T cell responses.
Schmitt M; Schmitt A; Wiesneth M; Hückelhoven A; Wu Z; Kuball J; Wang L; Schauwecker P; Hofmann S; Götz M; Michels B; Maccari B; Wuchter P; Eckstein V; Mertens T; Schnitzler P; Döhner H; Ho AD; Bunjes DW; Dreger P; Schrezenmeier H; Greiner J
Theranostics; 2017; 7(6):1705-1718. PubMed ID: 28529646
[No Abstract] [Full Text] [Related]
2. Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV.
Bunse L; Sommerer C; Tan CL; Korell F; Schmitt A; Hückelhoven-Krauss A; Neuber B; Mertens T; Platten M; Green EW; Zeier M; Schmitt M
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162953
[TBL] [Abstract][Full Text] [Related]
3. Induction of cytomegalovirus-specific T cell responses in healthy volunteers and allogeneic stem cell recipients using vaccination with messenger RNA-transfected dendritic cells.
Van Craenenbroeck AH; Smits EL; Anguille S; Van de Velde A; Stein B; Braeckman T; Van Camp K; Nijs G; Ieven M; Goossens H; Berneman ZN; Van Tendeloo VF; Verpooten GA; Van Damme P; Cools N
Transplantation; 2015 Jan; 99(1):120-7. PubMed ID: 25050468
[TBL] [Abstract][Full Text] [Related]
4. Soluble recombinant CMVpp65 spanning multiple HLA alleles for reconstitution of antiviral CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation.
Paine A; Oelke M; Tischer S; Heuft HG; Blasczyk R; Eiz-Vesper B
J Immunother; 2010 Jan; 33(1):60-72. PubMed ID: 19952955
[TBL] [Abstract][Full Text] [Related]
5. Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection.
Wang Z; La Rosa C; Lacey SF; Maas R; Mekhoubad S; Britt WJ; Diamond DJ
J Clin Virol; 2006 Mar; 35(3):324-31. PubMed ID: 16388983
[TBL] [Abstract][Full Text] [Related]
6. Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients.
Jacobson MA; Sinclair E; Bredt B; Agrillo L; Black D; Epling CL; Carvidi A; Ho T; Bains R; Adler SP
J Clin Virol; 2006 Mar; 35(3):332-7. PubMed ID: 16387547
[TBL] [Abstract][Full Text] [Related]
7. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection.
Gratama JW; van Esser JW; Lamers CH; Tournay C; Löwenberg B; Bolhuis RL; Cornelissen JJ
Blood; 2001 Sep; 98(5):1358-64. PubMed ID: 11520783
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus-specific CD4+ and CD8+ T-cells follow a similar reconstitution pattern after allogeneic stem cell transplantation.
Foster AE; Gottlieb DJ; Sartor M; Hertzberg MS; Bradstock KF
Biol Blood Marrow Transplant; 2002; 8(9):501-11. PubMed ID: 12374455
[TBL] [Abstract][Full Text] [Related]
9. Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations.
Gratama JW; Brooimans RA; van der Holt B; Sintnicolaas K; van Doornum G; Niesters HG; Löwenberg B; Cornelissen JJ
Cytometry B Clin Cytom; 2008 Jul; 74(4):211-20. PubMed ID: 18454493
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells.
Ozdemir E; St John LS; Gillespie G; Rowland-Jones S; Champlin RE; Molldrem JJ; Komanduri KV
Blood; 2002 Nov; 100(10):3690-7. PubMed ID: 12393402
[TBL] [Abstract][Full Text] [Related]
11. Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients.
Tormo N; Solano C; Benet I; Clari MA; Nieto J; de la Cámara R; López J; López-Aldeguer N; Hernández-Boluda JC; Remigia MJ; Garcia-Noblejas A; Gimeno C; Navarro D
Bone Marrow Transplant; 2010 Mar; 45(3):543-9. PubMed ID: 19617905
[TBL] [Abstract][Full Text] [Related]
12. Strong and sustained effector function of memory- versus naïve-derived T cells upon T-cell receptor RNA transfer: implications for cellular therapy.
Thomas S; Klobuch S; Besold K; Plachter B; Dörrie J; Schaft N; Theobald M; Herr W
Eur J Immunol; 2012 Dec; 42(12):3442-53. PubMed ID: 22930221
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous monitoring of cytomegalovirus-specific antibody and T-cell levels in seropositive heart transplant recipients.
Carbone J; Lanio N; Gallego A; Kern F; Navarro J; Muñoz P; Alonso R; Catalán P; Fernández-Yáñez J; Palomo J; Ruiz M; Fernández-Cruz E; Sarmiento E
J Clin Immunol; 2012 Aug; 32(4):809-19. PubMed ID: 22371292
[TBL] [Abstract][Full Text] [Related]
14. Kinetics of interferon-gamma producing cytomegalovirus (CMV)-specific CD4+ and CD8+ T lymphocytes and the risk of subsequent CMV viremia after allogeneic hematopoietic stem cell transplantation.
Eid AJ; Brown RA; Hogan WJ; Lahr BD; Eckel-Passow JE; Litzow MR; Razonable RR
Transpl Infect Dis; 2009 Dec; 11(6):519-28. PubMed ID: 19744286
[TBL] [Abstract][Full Text] [Related]
15. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection.
Lilleri D; Fornara C; Chiesa A; Caldera D; Alessandrino EP; Gerna G
Haematologica; 2008 Feb; 93(2):248-56. PubMed ID: 18245650
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12.
Jacobson MA; Sinclair E; Bredt B; Agrillo L; Black D; Epling CL; Carvidi A; Ho T; Bains R; Girling V; Adler SP
Vaccine; 2006 Jun; 24(25):5311-9. PubMed ID: 16701925
[TBL] [Abstract][Full Text] [Related]
17. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation.
Hakki M; Riddell SR; Storek J; Carter RA; Stevens-Ayers T; Sudour P; White K; Corey L; Boeckh M
Blood; 2003 Oct; 102(8):3060-7. PubMed ID: 12843000
[TBL] [Abstract][Full Text] [Related]
18. Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients.
Zhou W; Longmate J; Lacey SF; Palmer JM; Gallez-Hawkins G; Thao L; Spielberger R; Nakamura R; Forman SJ; Zaia JA; Diamond DJ
Blood; 2009 Jun; 113(25):6465-76. PubMed ID: 19369230
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Vaccination of Hematopoietic Cell Transplantation Recipients Improves Protective CD8 T-Cell Immunotherapy of Cytomegalovirus Infection.
Gergely KM; Podlech J; Becker S; Freitag K; Krauter S; Büscher N; Holtappels R; Plachter B; Reddehase MJ; Lemmermann NAW
Front Immunol; 2021; 12():694588. PubMed ID: 34489940
[TBL] [Abstract][Full Text] [Related]
20. Peptide Vaccination against Cytomegalovirus Induces Specific T Cell Response in Responses in CMV Seronegative End-Stage Renal Disease Patients.
Sommerer C; Schmitt A; Hückelhoven-Krauss A; Giese T; Bruckner T; Wang L; Schnitzler P; Meuer S; Zeier M; Schmitt M
Vaccines (Basel); 2021 Feb; 9(2):. PubMed ID: 33562163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
